D&D Pharmatech and First Bio Secure European Patent for Novel Brain Disease Drug NLY02
核心洞察
D&D Pharmatech (搜索) and First Bio (搜索) have received European Patent Office approval for NLY02, a neurodegenerative disease (搜索) treatment, following earlier U.S. patent protection.
NLY02 is an oral small molecule compound that crosses the blood-brain barrier and selectively inhibits RIPK2 (搜索) protein to protect brain neurons from neuroinflammation.
The drug is currently in preclinical development for treating Parkinson's disease (搜索) and Alzheimer's disease (搜索), with both companies planning continued collaboration for global commercialization.
D&D Pharmatech (搜索) and First Biotherapeutics (搜索) have secured a significant milestone in their joint neurodegenerative disease (搜索) program, receiving substance patent registration approval from the European Patent Office (EPO) for their investigational compound NLY02. This achievement extends their intellectual property protection to Europe, following earlier patent approval in the United States.
Novel Mechanism Targets Neuroinflammation
NLY02 represents a distinctive approach to treating degenerative brain diseases through its ability to cross the blood-brain barrier as an oral small molecule compound. The drug works by selectively inhibiting RIPK2 (搜索) protein, which triggers neuroinflammatory responses that contribute to neuronal damage. This mechanism positions NLY02 as a potential treatment for multiple neurodegenerative conditions, including Parkinson's disease (搜索) and Alzheimer's disease (搜索).
The compound is currently advancing through preclinical development, with both companies leveraging their complementary expertise to optimize its therapeutic potential. First Bio (搜索) handles candidate optimization and preclinical toxicity studies, while D&D Pharmatech (搜索) focuses on clinical strategy development and trial design.
Strategic Partnership Strengthens Global Position
The collaboration between D&D Pharmatech (搜索) and First Bio (搜索) began in 2018 with a joint development agreement that has continued to evolve. A company official emphasized the strategic importance of the European patent approval, stating, "With this registration decision, we have essentially completed our intellectual property protection framework in key global markets. This will serve as a core asset guaranteeing strong market exclusivity for partner companies in future global technology transfer discussions."
First Bio (搜索) CEO Kim Jae-eun highlighted the validation of NLY02's innovative approach, noting, "As NLY02's innovative mechanism and structural differentiation have been validated in Europe following the United States, we will concentrate our capabilities on generating meaningful results based on accumulated data."
Commercialization Framework Takes Shape
The patent approval strengthens the foundation for NLY02's potential global commercialization. D&D Pharmatech (搜索) CEO Lee Seul-ki expressed confidence in the program's trajectory, stating, "The foundation for NLY02's global commercialization has been further strengthened. We will work more closely with First Bio (搜索) to achieve tangible results in the global market."
Both companies have committed to continuing their partnership based on the intellectual property assets secured through this development, positioning themselves for potential technology transfer opportunities as the program advances through clinical development.